This supplement was independently developed by The American Journal of Managed Care and sponsored by Janssen Pharmaceuticals, Inc. with editorial direction.
This supplement to The American Journal of Managed Care provides an overview of the numerous metabolic defects that contribute to the development of hyperglycemia and type 2 diabetes mellitus (T2DM). New insights into the pathophysiology of T2DM, and the role of various organs and tissues such as the kidneys in regulating blood sugar, may potentially reveal pathophysiological mechanisms and defects that could be targeted for the insulin-independent pharmaceutical treatment of T2DM.
Muhammad A. Abdul-Ghani, MD, PhD
Associate Professor of Medicine
Division of Diabetes
University of Texas Health Science Center at San Antonio
San Antonio, Texas
Muhammad A. Abdul-Ghani, MD, PhD, has disclosed the following relevant commercial financial relationships or affiliations in the past 12 months:
Lectureship: Boehringer Ingelheim
Signed disclosures are on file at the office of The American Journal of Managed Care, Plainsboro, New Jersey.
Opinions expressed by authors, contributors, and advertisers are their own and not necessarily those of Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, the editorial staff, or any member of the editorial advisory board. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, is not responsible for accuracy of dosages given in articles printed herein. The appearance of advertisements in this publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality, or safety. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the articles or advertisements.